HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The metabotropic glutamate receptor 5 negative allosteric modulator fenobam: pharmacokinetics, side effects, and analgesic effects in healthy human subjects.

Abstract
Metabotropic glutamate receptor 5 (mGlu5) has been shown to modulate nociception in animals, but no mGlu5 antagonists have been developed commercially as analgesics. The mGlu5 antagonist fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] was originally evaluated for development as a nonbenzodiazepine anxiolytic. Fenobam is analgesic in numerous mouse pain models, acting exclusively through mGlu5 blockade. Furthermore, fenobam showed no signs of analgesic tolerance with up to 2 weeks of daily dosing in mice. Analgesic effects of fenobam in humans have not been reported. The purpose of this investigation was to evaluate fenobam pharmacokinetics and analgesic effects in humans. We first evaluated single-dose oral fenobam disposition in a parallel-group dose-escalation study in healthy volunteers. A second investigation tested the analgesic effects of fenobam in an established experimental human pain model of cutaneous sensitization using capsaicin cream and heat, in a double-blind placebo-controlled study. The primary outcome measure was the area of hyperalgesia and allodynia around the area applied with heat/capsaicin. Secondary outcome measures included nociception, measured as pain rating on a visual analog scale, heat pain detection threshold, and effects on cognition and mood. Fenobam plasma exposures showed considerable interindividual variability and were not linear with dose. Fenobam reduced sensitization vs placebo at a single timepoint (peak plasma concentration); we found no other difference between fenobam and placebo. Our results suggest highly variable fenobam disposition and minimal analgesic effects at the dose tested. We suggest that future studies testing analgesic effects of mGlu5 blockade are warranted, but such studies should use molecules with improved pharmacokinetic profiles.
AuthorsLaura F Cavallone, Michael C Montana, Karen Frey, Dorina Kallogjeri, James M Wages, Thomas L Rodebaugh, Tina Doshi, Evan D Kharasch, Robert W Gereau 4th
JournalPain (Pain) Vol. 161 Issue 1 Pg. 135-146 (01 2020) ISSN: 1872-6623 [Electronic] United States
PMID31568235 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics
  • Excitatory Amino Acid Antagonists
  • Imidazoles
  • Receptor, Metabotropic Glutamate 5
  • fenobam
Topics
  • Adult
  • Analgesics (pharmacokinetics, pharmacology, therapeutic use)
  • Double-Blind Method
  • Excitatory Amino Acid Antagonists (pharmacokinetics, pharmacology, therapeutic use)
  • Female
  • Healthy Volunteers
  • Humans
  • Hyperalgesia (drug therapy)
  • Imidazoles (pharmacokinetics, pharmacology, therapeutic use)
  • Male
  • Middle Aged
  • Pain (drug therapy)
  • Pain Measurement
  • Receptor, Metabotropic Glutamate 5 (antagonists & inhibitors)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: